- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Council for International Organizations of Medical Sciences.
Displaying page 1 of 1.
EudraCT Number: 2012-000482-21 | Sponsor Protocol Number: B4671001 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS GIVEN WITH ROUTINE PEDIATR... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003822-42 | Sponsor Protocol Number: B1971048 | Start Date*: 2015-01-30 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years. | |||||||||||||
Medical condition: Test the safety and immunogenicity of Bexsero used as a vaccine for Neisseria meningitidis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022303-22 | Sponsor Protocol Number: B1851047 | Start Date*: 2011-06-22 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||||||||||||
Full Title: A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO ASSESS THE IMPACT OF PROPHYLACTIC ANTIPYRETIC MEDICATION ON THE IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH ROUTINE PEDIATRIC VA... | |||||||||||||||||||||||
Medical condition: Pneumonia and ear infections caused by S pneumoniae. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014493-18 | Sponsor Protocol Number: B1971012(6108A1-2003-EU) | Start Date*: 2010-07-20 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in... | |||||||||||||
Medical condition: Healthy volunteers (prevention of bacterial meningitis). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) ES (Completed) PL (Completed) DE (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002145-11 | Sponsor Protocol Number: B1971015(6108A1-2005) | Start Date*: 2013-05-23 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A Phase 2, Randomized, Active-controlled, observer-blindED Trial, to Assess the Safety, Tolerability, and Immunogenicity of MCV4, TDAP Vaccine and bivalent RLP2086 Vaccine When Administered Concomi... | |||||||||||||
Medical condition: Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002137-38 | Sponsor Protocol Number: B1971011(6108A1-2007) | Start Date*: 2013-05-23 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A Phase 2, Randomized, ACTIVE-CONTROLLED, observer-blinded Trial, to Assess the Safety, Tolerability, and Immunogenicity of Gardasil® (HPV) Vaccine and BIVALENT RLP2086 Vaccine When Administered Co... | |||||||||||||
Medical condition: Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
